Kevin V Morris
Overview
Explore the profile of Kevin V Morris including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
122
Citations
5255
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang T, Hirons A, Doerflinger M, Morris K, Ledger S, Purcell D, et al.
Viruses
. 2024 Oct;
16(10).
PMID: 39459949
Human T cell leukaemia virus type-1 (HTLV-1) is an oncogenic retrovirus that causes lifelong infection in ~5-10 million individuals globally. It is endemic to certain First Nations populations of Northern...
2.
Idris A, Shrivastava S, Supramaniam A, Ray R, Shevchenko G, Acharya D, et al.
Nucleic Acid Ther
. 2024 Mar;
34(3):101-108.
PMID: 38530082
Long antisense RNAs (asRNAs) have been observed to repress HIV and other virus expression in a manner that is refractory to viral evolution. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),...
3.
Muskan M, Abeysinghe P, Cecchin R, Branscome H, Morris K, Kashanchi F
Mol Ther
. 2024 Feb;
32(9):2939-2949.
PMID: 38414242
Exosomes are extracellular vesicles (EVs) (∼50-150 nm) that have emerged as promising vehicles for therapeutic applications and drug delivery. These membrane-bound particles, released by all actively dividing cells, have the...
4.
Idris A, Supramaniam A, Tayyar Y, Kelly G, McMillan N, Morris K
Antiviral Res
. 2024 Jan;
222:105815.
PMID: 38246206
There remains a striking overall mortality burden of COVID-19 worldwide. Given the waning effectiveness of current SARS-CoV-2 antivirals due to the rapid emergence of new variants of concern (VOC), we...
5.
Urak R, Gittins B, Soemardy C, Grepo N, Goldberg L, Maker M, et al.
Cancers (Basel)
. 2023 Jun;
15(10).
PMID: 37345185
Short hairpin RNAs (shRNAs) have emerged as a powerful tool for gene knockdown in various cellular systems, including chimeric antigen receptor (CAR) T cells. However, the elements of shRNAs that...
6.
Frederickson R, Ritter T, Morris K
Mol Ther
. 2023 Apr;
31(5):1189-1190.
PMID: 37054709
No abstract available.
7.
Supramaniam A, Tayyar Y, Clarke D, Kelly G, Acharya D, Morris K, et al.
J Microbiol Immunol Infect
. 2023 Mar;
56(3):516-525.
PMID: 36934064
RNA interference (RNAi) is an emerging and promising therapy for a wide range of respiratory viral infections. This highly specific suppression can be achieved by the introduction of short-interfering RNA...
8.
Cecchin R, Troyer Z, Witwer K, Morris K
Mol Ther
. 2023 Jan;
31(5):1225-1230.
PMID: 36698310
Extracellular vesicles (EVs) are esteemed as a promising delivery vehicle for various genetic therapeutics. They are relatively inert, non-immunogenic, biodegradable, and biocompatible. At least in rodents, they can even transit...
9.
Scott T, Soemardy C, Ray R, Morris K
NAR Cancer
. 2023 Jan;
5(1):zcac046.
PMID: 36644398
Human T-lymphotropic virus type I (HTLV-I) infects CD4+ T-cells resulting in a latent, life-long infection in patients. Crosstalk between oncogenic viral factors results in the transformation of the host cell...
10.